Abstract | AIMS: RESULTS: The average thickness of the retina at baseline was 632 μm, the medial BCVA was 0.8 logMAR, and corrected intraocular pressure was 13.7 mmHg. The maximum decrease in mean retinal thickness was observed at four weeks following the treatment and was 365 μm (-267 μm) and visual acuity improved by an average of two lines and was 0.6 logMAR. The largest increase in mean retinal thickness to average of 528 μm (+164 μm) occurred at 16 weeks and the average BCVA was 0.614 lines BCVA logMAR. In one eye, there was a steroid cataract development after the third dose of dexamethasone implant of 0.7 mg. CONCLUSIONS:
|
Authors | Dominik Zalewski, Dorota Raczyńska, Krystyna Raczyńska |
Journal | Mediators of inflammation
(Mediators Inflamm)
Vol. 2014
Pg. 364143
( 2014)
ISSN: 1466-1861 [Electronic] United States |
PMID | 24659860
(Publication Type: Journal Article, Observational Study)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Dexamethasone
- Ranibizumab
|
Topics |
- Aged
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Bevacizumab
- Cataract
(chemically induced)
- Dexamethasone
(administration & dosage, adverse effects, therapeutic use)
- Diabetic Retinopathy
(drug therapy)
- Humans
- Intravitreal Injections
- Macular Edema
(drug therapy)
- Male
- Middle Aged
- Ranibizumab
- Retina
(drug effects)
- Retrospective Studies
- Time Factors
|